LeMaitre Vascular
Nasdaq LMAT · Burlington, MA
Works in Cardiovascular · Genetic & rare · Renal & urogenital · Women's health
LeMaitre Vascular is a clinical trial sponsor based in Burlington, MA, listed as Nasdaq LMAT. It has 5 active clinical trials with 668 planned participants, in Cardiovascular, Genetic & rare, Renal & urogenital and Women's health. Since 2021 it has completed 2 trials and stopped 1 early. Its FDA record on file shows 1 inspection, 1 warning letter and 1 recall.
Trial track record · since 2021
FDA record
Recent FDA actions
Financials · Nasdaq LMAT
Pipeline · 5 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about LeMaitre Vascular
Yes. FDA has published 1 warning letter naming LeMaitre Vascular; the latest was posted on 2025-08-26. Each letter links to FDA's own posting.
FDA has posted 1 inspection classification naming LeMaitre Vascular. The latest inspection ended on 2026-06-25 and was classified OAI (official action indicated). FDA posts a classification after its review, often months after the inspection ended.
Yes. FDA's enforcement reports list 1 recall by LeMaitre Vascular; the latest, reported on 2026-10-14, is a Class II recall.
LeMaitre Vascular is lead sponsor of 5 active clinical trials on ClinicalTrials.gov, with 668 planned participants, in Cardiovascular, Genetic & rare, Renal & urogenital, Women's health. Since 2021 it has completed 2 trials and stopped 1 early.
LeMaitre Vascular is based in Burlington, MA and is listed as Nasdaq LMAT. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with LeMaitre Vascular; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2025-03-10.
The FDA record counts inspection classifications, warning letters and recalls FDA has published that name this company. Compare it with the industry in the free CDMO FDA inspection lookup.
Approve Suite is not affiliated with LeMaitre Vascular.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.